Ovarian Cancer Clinical Trial Analysis 2025: 200+ Pipeline Drugs, PARP Inhibitors, Immunotherapies, and Targeted Strategies Drive Innovation | DelveInsight

DelveInsight's "Ovarian Cancer - Pipeline Insight, 2025" reviews over 200+ therapies in development for ovarian cancer, one of the most challenging gynecologic malignancies with high relapse rates. Despite advances with PARP inhibitors and chemotherapy, many patients eventually develop resistance, underscoring the urgent unmet need in the ovarian cancer treatment market.

The pipeline is diversifying with next-generation PARP inhibitors, DNA damage response (DDR) modulators, and targeted therapies such as anti-angiogenic agents and antibody-drug conjugates. Immuno-oncology is gaining momentum, with checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies being evaluated in combination regimens to enhance durable responses. In addition, precision oncology approaches leveraging biomarkers like BRCA mutations, HRD status, and other molecular signatures are driving more individualized treatment strategies.

With ovarian cancer clinical trials spanning small molecules, biologics, and cellular therapies, the therapeutic landscape is shifting beyond chemotherapy toward multi-modality, personalized care. As late-stage candidates advance, the ovarian cancer market is poised to transform, offering patients expanded options, longer survival, and improved quality of life.

Interested in learning more about the current treatment landscape and the key drivers shaping the Ovarian Cancer pipeline? Click here: https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Ovarian Cancer Pipeline Report
• DelveInsight's Ovarian Cancer clinical trial analysis depicts a strong space with 180+ active players working to develop 200+ pipeline drugs for Ovarian Cancer treatment.
• The leading Ovarian Cancer companies include Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others are evaluating their lead assets to improve the Ovarian Cancer treatment landscape.
• Key Ovarian Cancer pipeline therapies in various stages of development include Stenoparib, Adavosertib, Tedopi, CriPec, Nivolumab, Pembrolizumab, Batiraxcept, Upifitamab Rilsodotin, RUBRACA, Avutometinib, Vigil, Veliparib, Seribantumab, Durvalumab, Oregovomab, Nemvaleukin alfa, ROZLYTREK, LYNPARZA, Niraparib, Maveropepimut-S, Relacorilant, and others.
• In September 2025, Corcept Therapeutics (NASDAQ: CORT) announced that the FDA accepted its NDA for relacorilant to treat platinum-resistant ovarian cancer, with a PDUFA date set for July 11, 2026.
• In August 2025, Allarity Therapeutics received FDA Fast Track designation for stenoparib, its investigational dual PARP and WNT inhibitor for advanced ovarian cancer.
• In June 2025, Pheast Therapeutics announced that the FDA granted Fast Track Designation to PHST001, an anti-CD24 antibody, for treating advanced platinum-resistant ovarian cancer and in combination with chemotherapy for platinum-sensitive ovarian cancer.
• In June 2025, Guardant Health, Inc. (Nasdaq: GH) announced that its Shield multi-cancer detection (MCD) test received Breakthrough Device designation from the FDA. The methylation-based blood test is designed to screen for multiple cancers-including bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic-in adults aged 45+ at average risk.
• In May 2025, PMV Pharmaceuticals (Nasdaq: PMVP) reported Q1 results and corporate updates, announcing interim Phase 2 PYNNACLE trial data expected mid-2025. The analysis will include around 50 patients, with 40% from the ovarian cancer cohort, each followed for at least 18 weeks. The trial evaluates rezatapopt monotherapy in TP53 Y220C and KRAS wild-type advanced solid tumors.
• In May 2025, Verastem Oncology (Nasdaq: VSTM) announced FDA approval of AVMAPKITM FAKZYNJATM CO-PACK (avutometinib and defactinib) for treating KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) in adults previously treated with systemic therapy. It is the first and only FDA-approved therapy for this indication.
• In May 2025, UTR Therapeutics Inc. announced the submission of an IND application to the FDA for UTRxM1-18, a novel therapy designed to target c-MYC driven cancers, including triple-negative breast, pancreatic, colorectal, and ovarian cancers. Leveraging its 3'UTR engineering platform, UTRxM1-18 selectively degrades cancer-specific transcripts while sparing healthy cells. In preclinical studies, the drug showed strong, dose-dependent efficacy across tumor types with no dose-limiting toxicities.

Request a sample and discover the recent breakthroughs happening in the Ovarian Cancer pipeline landscape at https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ovarian Cancer Overview
Ovarian cancer is a malignant tumor that originates in the ovaries, the female reproductive glands responsible for producing eggs and hormones. It is often referred to as a "silent killer" because symptoms-such as bloating, pelvic pain, and frequent urination-are typically vague and may not appear until the disease has progressed to an advanced stage. The majority of cases are epithelial ovarian cancers, which arise from the surface layer of the 0vary, while less common types include germ cell and stromal tumors.

Diagnosis usually involves imaging, pelvic examination, blood tests (such as CA-125), and confirmatory biopsy or surgery. Treatment typically consists of a combination of surgery to remove as much of the tumor as possible (debulking) and chemotherapy. Targeted therapies, such as PARP inhibitors for BRCA-mutated cancers, and anti-angiogenic agents have improved outcomes in some subtypes. However, recurrence is common, and ovarian cancer remains one of the leading causes of gynecologic cancer deaths worldwide.

Find out more about Ovarian Cancer medication at https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ovarian Cancer Treatment Analysis: Drug Profile
Atezolizumab (Genentech):
Atezolizumab is a humanized IgG1 monoclonal antibody designed to block PD-L1 from binding to its receptors PD-1 and B7.1, thereby enhancing T-cell activity against tumors. Engineered with a specific amino acid modification to remove Fc-effector function, it minimizes immune cell depletion. Atezolizumab is currently in Phase III clinical trials for the treatment of ovarian cancer.

Tisotumab Vedotin (Genmab):
Tisotumab vedotin is an antibody-drug conjugate (ADC) that targets tissue factor (TF), a protein involved in tumor growth and blood vessel formation. The antibody is linked to the cytotoxic agent MMAE via a cleavable linker, allowing targeted delivery of the toxin to TF-expressing tumor cells. The drug is currently in Phase II clinical trials for ovarian cancer.

SON-1010 (Sonnet Biotherapeutics):
SON-1010 is a tumor-targeted formulation of native human IL-12 developed using Sonnet's FHAB® platform, which extends its circulation time and activity. It is being investigated in combination with atezolizumab under a collaboration with Roche for treating platinum-resistant ovarian cancer (PROC). SON-1010 is currently in Phase I/II development.

Learn more about the novel and emerging Ovarian Cancer pipeline therapies at https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ovarian Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Ovarian Cancer Pipeline Report
• Coverage: Global
• Key Ovarian Cancer Companies: Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others.
• Key Ovarian Cancer Pipeline Therapies: Stenoparib, Adavosertib, Tedopi, CriPec, Nivolumab, Pembrolizumab, Batiraxcept, Upifitamab Rilsodotin, RUBRACA, Avutometinib, Vigil, Veliparib, Seribantumab, Durvalumab, Oregovomab, Nemvaleukin alfa, ROZLYTREK, LYNPARZA, Niraparib, Maveropepimut-S, Relacorilant, and others.

To dive deep into rich insights for drugs used for Ovarian Cancer treatment, visit: https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Ovarian Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Ovarian Cancer Pipeline Therapeutics
6. Ovarian Cancer Pipeline: Late-Stage Products (Phase III)
7. Ovarian Cancer Pipeline: Mid-Stage Products (Phase II)
8. Ovarian Cancer Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.